Top 10 Later Stage Investors in Biotechnology, Pharma & Life Sciences
| Rank | Investor Name |
|---|---|
| 1 | RA Capital Management |
| 2 | ARCH Venture Partners |
| 3 | Ally Bridge Group |
| 4 | Forbion Capital Partners |
| 5 | Gilde Healthcare Partners |
| 6 | SR One Capital Management |
| 7 | Dimension |
| 8 | Illumina Ventures |
| 9 | Nextech Invest |
| 10 | GV |
Platform science and pharma partnership appetite drive the category, with specialist funds leading most rounds. These firms are ranked by rounds led rather than participation, so this is the short list of investors actually pricing later stage deals in the category.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Create a free account and get the contacts for the investors above.
Rankings cover January 2025 to July 2026 investment activity in US and Canada companies. Seed and early-stage rankings measure deal participation, not suitability for every raise.